molecule.co.ukCrawled Nov 9, 2026
Bovex 2.265% is a broad spectrum worm drench for cattle and sheep for the control of mature and immature forms of gastro-intestinal roundworms, lungworms and tapeworms. The product is ovicidal against nematode eggs.
Chanaverm 7.5% is a broad spectrum anthelmintic for the treatment and control of gastro-intestinal and pulmonary nematode infections in cattle and sheep.
For the treatment of flea and tick infestations in dogs.
This veterinary medicinal product provides immediate and persistent killing activity for 1 month for fleas and ticks.
Molecule brings together clinic, pharmacy and veterinary care: prescriptions, medicines and expert advice for people and their animals, from one trusted UK-regulated group.
Molecule Group plc grants **47,619 share options** to its Chair, **Susan Clement Davies**, with an exercise price of **£2.10 per share**. The move aligns with equity-based compensation practices for executive roles. The company also reports a separate buyback activity by BlackRock’s Greater Europe Investment Trust.
Oct 2026kalkinemedia.comNews article
Molecule Group, formerly Vulcan Two, consolidates the UK’s regulated e-pharmacy market, targeting the expanding private healthcare sector. The company’s founders previously succeeded in merging online contact lens providers. It aims to scale operations in a highly regulated industry through strategic acquisitions and market integration.
Oct 2026Edison GroupNews article
Stephenson Harwood advises Vulcan Two Group on acquiring three companies—CloudRx Holdings, Hyperdrug Pharmaceuticals, and Webmed Pharmacy—for up to £41.7 million. The firm also supports a £40 million fundraising on AIM to build the UK’s leading regulated ePharmacy platform. The transaction uses a reverse takeover structure under AIM Rules.
Mar 2026stephensonharwood.comNews article
A listed e-pharmacy group secures a Leeds distribution centre to bolster its operations. The company previously acquired three businesses in a £42 million deal last month. The new facility supports its buy-and-build growth strategy in the online pharmacy sector.
Mar 2026Insider Media LtdNews article
